Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07206342

Evaluation of the Non-inferiority of Resorbable Gelatin Embolization Compared to Embolization Combined With Endometrial Aspiration for the Management of Hemorrhagic Uterine Vascular Abnormalities Following Premature Termination of Pregnancy

The goal of this clinical trial is to determine the best treatment for patients who experience vaginal bleeding following a premature termination of pregnancy.

The main questions it aims to answer are:

* Evaluate the effectiveness of embolization alone versus embolization followed by aspiration in stopping bleeding * Evaluate its effectiveness in restoring the menstrual cycle. * What are the complications associated with the two procedures? * What is their impact on future fertility?

The researchers will evaluate the patients over a period of 12 months.

Participants will:

* Undergo one of the two procedures (procedure 1: embolization alone and procedure 2: embolization combined with aspiration). * Will participate in regular follow-ups to monitor the risk of recurrence of -bleeding and complications associated with the two treatments * Will undergo imaging tests to assess the persistence of bleeding after the procedure

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Ten to 15% of pregnancies end in the first trimester. Voluntary termination of pregnancy and spontaneous miscarriage, the two main causes of pregnancy loss, are managed medically or surgically in order to remove the intrauterine residue and restore a vacant uterus. In cases of incomplete evacuation, uterine retention may persist in approximately 1% of all pregnancies and up to 40% of pregnancy terminations in the second trimester.

The management of uterine retention depends on the clinical presentation and its vascularization on ultrasound. If it is not vascularized or only slightly vascularized, simple aspiration or monitoring is considered. In cases of hypervascularity, treatment is debated given the variable amount of bleeding and the sometimes spontaneously favorable outcome. Doppler criteria (systolic peak velocity, resistance index, or vascular invasion of the myometrium) have been described to select patients who are likely to have a spontaneous favorable outcome from those who require invasive management. In cases of hypervascularized intrauterine retention with negative findings on Doppler ultrasound, performing endometrial aspiration carries a significant risk of severe bleeding during the procedure and is generally preceded by embolization in order to minimize this risk (embolization + aspiration). Aspiration induces adhesions (synechiae) that can impair the patient's future fertility.

Recent publications show the effectiveness of temporary embolization alone using resorbable gelatin fragments to stop bleeding. Our team has reported uterine emptiness rates of approximately 75% at 1 month and 95% at 3 months after embolization alone with resorbable gelatin.

The objective of this study is therefore to evaluate the non-inferiority of embolization alone with resorbable gelatin compared to embolization followed by endometrial aspiration in patients with hypervascularized and hemorrhagic intrauterine retention following premature termination of pregnancy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who experienced a miscarriage within 3 months
  • Patient with gynecological bleeding
  • Patient presenting with hypervascularized uterine retention with negative Doppler ultrasound findings (endometrial hypervascularization with 1) systolic peak velocity greater than 70 cm/s and/or 2) resistance index (RI) within the retention < 0.5)
  • Patient affiliated to french social security
  • Patient who has signed the written informed consent form

Exclusion criteria

  • Patient presenting to the emergency department with hemorrhagic shock: systolic blood pressure < 90 mmHg associated with tachycardia > 120 bpm
  • Severe renal failure (glomerular filtration rate < 30 mL/min)
  • Medical history of severe allergy to iodinated contrast media
  • Severe coagulation disorders (platelets <50G/L, PT < 50%)
  • Anticoagulant and/or antiplatelet agent that cannot be discontinued a few days before the procedure
  • Patient referred to in Articles L1121-5, L1121-6, and L1121-8 of the French Public Health Code
  • Staff with a hierarchical relationship to the principal investigator
  • Patient in the exclusion period of another study
  • Patient cannot be contacted in an emergency
  • Participation in other interventional studies during the study period

Treatment and study plan

embolization therapy

Procedure

Patients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.

Other names: embolic agent

embolization followed by aspiration

Procedure

Patients will undergo embolization prior to endometrial aspiration. Embolization will be performed in the same manner as in group "Embolization alone" but will be followed within 48 hours by a second procedure to remove the intrauterine residue that will have been devascularized (= deprived of blood) by the embolization.

Other names: endometrial aspiration, intrauterine aspiration, hysteroscopy

Primary outcomes

  1. Clinical success post-procedure as assessed by Doppler-ultrasound

    Time frame: From baseline to 3 months after procedure

    The primary endpoint is clinical success defined by a null uterine cavity on follow-up Doppler ultrasound and no persistent or recurrent bleeding requiring a new procedure

Secondary outcomes

  1. Persistence or recurrence of bleeding at 1 month follow-up in both groups.

    Time frame: From baseline to 1 month

    Evaluate the effectiveness of embolization alone versus embolization followed by aspiration at 1 month of follow-up in stopping bleeding in patients with hypervascularized hemorrhagic uterine retention following premature termination of pregnancy.

  2. Safety of both treatments

    Time frame: Fom intervention to 90 days after

    Complications attributable to procedures within 90 days of admission according to the Clavien-Dindo classification

  3. the effectiveness of embolization alone compared to embolization followed by uterine evacuation at 1 month after procedure

    Time frame: From intervention to 1 month

    Measurement of uterine emptiness on Doppler ultrasound at 1 month

  4. the effectiveness of embolization alone compared to embolization followed by uterine evacuation at 3 months after procedure

    Time frame: From intervention to 3 months

    Measurement of uterine emptiness on Doppler ultrasound at 3 months

  5. the impact of embolization alone compared to embolization followed by aspiration on the resumption of the menstrual cycle

    Time frame: From intervention to 12 months

    Time between intervention and resumption of menstrual cycle

  6. the impact of embolization alone versus embolization followed by aspiration on subsequent fertility

    Time frame: From intervention to 12 months

    New pregnancy occurring within 12 months of the patient's admission

  7. If infertility diagnosis within 12 months, the rate of synechiae found between the two groups.

    Time frame: From intervention to 12 months

    Uterine adhesions on hysteroscopy performed for infertility assessment.

Study contacts

Contact information is provided by the study sponsor or research team.

AyseGul Sahan

CONTACT

[email protected]

0476766872

Marine Faure

CONTACT

[email protected]

0476766872

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Collaborators

  • Centre Hospitalier Universitaire Saint Etienne, France, 43055
  • University Hospital, Bordeaux
  • University Hospital, Clermont-Ferrand

Registry information

Acronym: NIEMBUT

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Oct 3, 2025
Registry last updated
Oct 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.